Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,506 total abstracts
  1. Abstract 14972026-09-01 · 14:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-897 study)
    L. Paz-Ares, H. Borghaei, S. Modi · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 16422026-09-03 · 13:45 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    E. Winer, M. Krop, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 43232026-09-02 · 19:00 CT · S100A
    EV-800: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    A. Spira, J. Cortes, M.C. Garassino · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  4. Abstract 40662026-09-04 · 18:00 CT · S100A
    EV-352: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    H. Borghaei, M. Krop · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  5. Abstract 16932026-09-03 · 18:30 CT · S100A
    Quality of life outcomes with Tecentriq in patients with TNBC
    C. Robert, S. Modi, A. Spira, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 92932026-09-03 · 16:30 CT · Hall B1
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-429
    S. Modi, J. Cortes, C. Saura, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  7. Abstract 44942026-09-03 · 16:45 CT · S406
    IMpower-592: Tecentriq (atezolizumab) maintenance in HCC
    H. Borghaei, L. Paz-Ares, S. Modi, et al. · Karolinska Institute
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  8. Abstract 11892026-09-02 · 15:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-522
    S. Tolaney, N. Rizvi, M. Reck, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 91032026-09-03 · 20:00 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    E. Winer, H. Borghaei · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  10. Abstract 11292026-09-05 · 15:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-200 study)
    J. Cortes, R. Herbst · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 13622026-09-01 · 13:00 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    R. Herbst, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 16292026-09-01 · 16:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-822
    L. Paz-Ares, G. Curigliano · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract 66752026-09-05 · 18:00 CT · S100A
    CheckMate-197: Opdivo (nivolumab) 3L+ in RCC
    R. Herbst, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  14. Abstract 42642026-09-01 · 14:15 CT · E450
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    R. Herbst, H. Rugo, M. Reck · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  15. Abstract 41752026-09-03 · 19:45 CT · Hall B1
    ASCENT-737: Trodelvy (sacituzumab govitecan) maintenance in urothelial carcinoma
    R. Herbst, C. Robert · Royal Marsden Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  16. Abstract 97042026-09-02 · 16:30 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    E. Winer, G. Curigliano · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  17. Abstract 58082026-09-02 · 14:00 CT · S100A
    Quality of life outcomes with Lynparza in patients with prostate
    T. Mok, P. Schmid · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  18. Abstract 11152026-09-04 · 15:30 CT · S100A
    OlympiA-721: Lynparza (olaparib) maintenance in HR+ breast cancer
    S. Antonia, M. Krop, H. Borghaei · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 46382026-09-01 · 19:00 CT · Hall B1
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-956
    M.C. Garassino, S. Modi · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  20. Abstract 10512026-09-02 · 18:00 CT · E450
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    T. Mok, J. Brahmer, M. Krop, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 10532026-09-05 · 20:15 CT · E450
    MONARCH-151: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    J. Cortes, P. Schmid, T. Mok · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 11892026-09-05 · 18:00 CT · S406
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-913 study)
    J. Brahmer, M.C. Garassino, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 42792026-09-05 · 18:00 CT · Hall B1
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    H. Rugo, N. Rizvi, P. Schmid · Royal Marsden Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  24. Abstract 15302026-09-03 · 21:00 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    M.C. Garassino, S. Antonia, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 44682026-09-04 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-797 study)
    C. Saura, S. Modi, E. Winer, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  26. Abstract 44632026-09-01 · 18:00 CT · S406
    DESTINY-Breast-34: Enhertu (trastuzumab deruxtecan) neoadjuvant in gastric
    A. Spira, G. Curigliano · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  27. Abstract 60132026-09-02 · 18:15 CT · S406
    Quality of life outcomes with Opdivo in patients with RCC
    E. Winer, S. Peters, C. Robert, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  28. Abstract 99592026-09-02 · 18:00 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for SCLC: KEYNOTE-351
    E. Winer, P. Schmid · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  29. Abstract 91142026-09-01 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-572 study)
    J. Brahmer, H. Rugo, S. Tolaney, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  30. Abstract 93802026-09-02 · 16:30 CT · Hall B1
    PACIFIC-619: Imfinzi (durvalumab) neoadjuvant in SCLC
    C. Robert, G. Curigliano, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  31. Abstract 91912026-09-05 · 14:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-70
    S. Peters, M.C. Garassino, L. Paz-Ares, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 59432026-09-04 · 18:30 CT · E450
    OlympiA-787: Lynparza (olaparib) adjuvant in ovarian
    S. Peters, C. Saura, S. Tolaney, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  33. Abstract 42112026-09-04 · 13:30 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-410 study)
    P. Schmid, R. Herbst, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  34. Abstract 98652026-09-05 · 19:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-395 study)
    A. Spira, H. Rugo, N. Rizvi, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  35. Abstract 41482026-09-02 · 16:30 CT · Hall B1
    Long-term follow-up of Enhertu 2L for gastric: DESTINY-Breast-415
    S. Modi, C. Robert, M. Reck · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  36. Abstract 19302026-09-01 · 13:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-594
    G. Curigliano, P. Schmid · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 98452026-09-03 · 19:15 CT · S100A
    Quality of life outcomes with Imfinzi in patients with SCLC
    M. Reck, J. Brahmer, M. Krop, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  38. Abstract 55092026-09-01 · 19:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-122
    S. Tolaney, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  39. Abstract 13382026-09-05 · 19:45 CT · Hall B1
    PALOMA-583: Ibrance (palbociclib) 2L in HR+ breast cancer
    C. Robert, M.C. Garassino, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 93672026-09-05 · 20:45 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with NSCLC
    E. Winer, J. Cortes, T. Mok, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  41. Abstract 49692026-09-02 · 15:15 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    M. Reck, N. Rizvi · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  42. Abstract 91592026-09-03 · 20:45 CT · S406
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-906
    H. Borghaei, E. Winer · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  43. Abstract 14482026-09-05 · 14:30 CT · E450
    OlympiA-986: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    M. Reck, M. Krop, F. Andre, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 17562026-09-05 · 14:00 CT · S406
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-439
    J. Brahmer, M. Reck · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 11692026-09-02 · 20:15 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    M. Krop, J. Cortes, S. Modi, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 19082026-09-03 · 14:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-424
    C. Saura, F. Andre, R. Herbst, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 92212026-09-03 · 15:30 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-55
    R. Herbst, M. Reck · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  48. Abstract 16602026-09-01 · 13:30 CT · S100A
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-547
    C. Saura, E. Winer, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  49. Abstract 67282026-09-05 · 16:45 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-919 study)
    H. Borghaei, J. Cortes, M.C. Garassino, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  50. Abstract 69492026-09-01 · 19:45 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in RCC
    S. Antonia, J. Cortes, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  51. Abstract 17412026-09-02 · 18:15 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-807
    A. Spira, M. Reck, H. Borghaei, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 14152026-09-02 · 18:45 CT · S406
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-932
    J. Cortes, C. Saura · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 12922026-09-05 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-649 study)
    C. Robert, S. Modi, M. Reck, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 13772026-09-04 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-278 study)
    J. Brahmer, P. Schmid, E. Winer, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 10362026-09-02 · 20:45 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Modi, H. Borghaei · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 40102026-09-03 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-621
    R. Herbst, F. Andre, C. Robert, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  57. Abstract 41602026-09-03 · 14:30 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with biliary tract
    L. Paz-Ares, S. Tolaney, T. Mok · Massachusetts General Hospital
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  58. Abstract 19642026-09-03 · 16:15 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-422 study)
    M. Krop, E. Winer, J. Brahmer, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 93802026-09-02 · 18:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-948
    J. Cortes, M. Krop, S. Tolaney · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  60. Abstract 19552026-09-05 · 18:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-727
    F. Andre, H. Rugo, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 45092026-09-01 · 19:00 CT · S406
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-235 study)
    H. Borghaei, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  62. Abstract 17172026-09-04 · 13:00 CT · E450
    MONARCH-655: Verzenio (abemaciclib) 1L in HR+ breast cancer
    H. Rugo, J. Brahmer, A. Spira · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 17662026-09-02 · 15:30 CT · E450
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-629
    C. Robert, R. Herbst, S. Antonia, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 15032026-09-05 · 15:30 CT · E450
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    S. Modi, P. Schmid, F. Andre, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 49642026-09-01 · 13:30 CT · S100A
    Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-500
    R. Herbst, F. Andre, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  66. Abstract 12432026-09-05 · 18:00 CT · S406
    PALOMA-432: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    G. Curigliano, T. Mok, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 93292026-09-01 · 21:00 CT · E450
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-337
    T. Mok, S. Modi, J. Cortes, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  68. Abstract 47792026-09-04 · 14:45 CT · S406
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    G. Curigliano, C. Saura, H. Borghaei · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  69. Abstract 17992026-09-01 · 19:15 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    C. Robert, G. Curigliano, C. Saura · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  70. Abstract 44802026-09-05 · 16:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-869
    M. Reck, S. Antonia · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  71. Abstract 17952026-09-01 · 19:00 CT · Hall B1
    DESTINY-Breast-251: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    G. Curigliano, M. Krop · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  72. Abstract 10052026-09-03 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-362
    M. Reck, S. Tolaney, C. Robert · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 42732026-09-01 · 16:00 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-320
    A. Spira, E. Winer, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  74. Abstract 14042026-09-02 · 14:00 CT · S406
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-732
    H. Borghaei, S. Peters, L. Paz-Ares · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  75. Abstract 60042026-09-03 · 19:30 CT · S406
    KEYNOTE-841: Keytruda (pembrolizumab) adjuvant in RCC
    M. Krop, S. Peters, G. Curigliano · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  76. Abstract 56672026-09-05 · 15:45 CT · S406
    Long-term follow-up of Lynparza neoadjuvant for ovarian: OlympiA-527
    E. Winer, T. Mok · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  77. Abstract 42782026-09-05 · 15:45 CT · E450
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-549 study)
    F. Andre, S. Modi, H. Rugo · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  78. Abstract 90022026-09-05 · 14:30 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    S. Tolaney, P. Schmid, H. Borghaei · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  79. Abstract 59432026-09-05 · 18:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-977
    R. Herbst, H. Borghaei, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  80. Abstract 99282026-09-02 · 21:15 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-444
    G. Curigliano, H. Borghaei · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  81. Abstract 45142026-09-01 · 21:30 CT · Arie Crown Theater
    ASCENT-411: Trodelvy (sacituzumab govitecan) neoadjuvant in urothelial carcinoma
    H. Borghaei, N. Rizvi, P. Schmid · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  82. Abstract 64482026-09-01 · 15:00 CT · S100A
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-402
    R. Herbst, L. Paz-Ares, J. Brahmer, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  83. Abstract 41382026-09-04 · 16:30 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    C. Robert, J. Cortes, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  84. Abstract 99722026-09-04 · 21:45 CT · S100A
    FLAURA-612: Tagrisso (osimertinib) maintenance in NSCLC
    J. Cortes, M. Krop, J. Brahmer · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  85. Abstract 98242026-09-01 · 13:45 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for NSCLC: KEYNOTE-615
    A. Spira, M. Reck, S. Antonia, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  86. Abstract 13362026-09-02 · 16:15 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-41
    T. Mok, M. Krop, P. Schmid · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  87. Abstract 64632026-09-02 · 18:30 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    S. Tolaney, J. Brahmer, C. Robert · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  88. Abstract 46832026-09-04 · 20:45 CT · S100A
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-8
    P. Schmid, S. Peters, G. Curigliano · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  89. Abstract 95672026-09-02 · 14:00 CT · S100A
    KEYNOTE-527: Keytruda (pembrolizumab) 1L in metastatic melanoma
    H. Rugo, C. Robert, S. Modi · MD Anderson Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  90. Abstract 59432026-09-05 · 15:00 CT · E450
    OlympiA-751: Lynparza (olaparib) maintenance in prostate
    S. Modi, F. Andre · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  91. Abstract 11792026-09-01 · 16:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-28 study)
    L. Paz-Ares, H. Borghaei, M. Krop, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  92. Abstract 18562026-09-02 · 18:15 CT · Hall B1
    IMpower-288: Tecentriq (atezolizumab) neoadjuvant in TNBC
    H. Rugo, S. Modi, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  93. Abstract 46812026-09-01 · 20:15 CT · S100A
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-268
    L. Paz-Ares, N. Rizvi · National Cancer Center Japan
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  94. Abstract 56432026-09-02 · 13:30 CT · S406
    OlympiA-833: Lynparza (olaparib) neoadjuvant in ovarian
    H. Borghaei, P. Schmid, E. Winer, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  95. Abstract 15402026-09-02 · 14:00 CT · S406
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-858
    S. Tolaney, M. Reck, P. Schmid · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 65172026-09-03 · 20:45 CT · S406
    CheckMate-304: Opdivo (nivolumab) 2L in RCC
    M. Reck, A. Spira · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  97. Abstract 104242026-09-01 · 20:45 CT · S406
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-434
    C. Robert, J. Brahmer, N. Rizvi, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  98. Abstract 99842026-09-01 · 15:15 CT · Hall B1
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-189
    C. Robert, S. Tolaney · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  99. Abstract 42932026-09-01 · 20:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-600
    S. Antonia, E. Winer · National Cancer Center Japan
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  100. Abstract 15102026-09-02 · 13:30 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-568
    A. Spira, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 45472026-09-04 · 21:30 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in HCC
    F. Andre, N. Rizvi, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  102. Abstract 17722026-09-03 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-372 study)
    P. Schmid, T. Mok · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  103. Abstract 15582026-09-03 · 16:15 CT · S406
    Quality of life outcomes with Keytruda in patients with TNBC
    C. Robert, J. Cortes, C. Saura, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  104. Abstract 97242026-09-03 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-412 study)
    P. Schmid, M.C. Garassino · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  105. Abstract 42512026-09-05 · 19:15 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-784
    C. Saura, J. Cortes, S. Tolaney, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  106. Abstract 62682026-09-02 · 19:00 CT · Hall B1
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-840
    M. Krop, H. Borghaei, P. Schmid · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  107. Abstract 40452026-09-01 · 21:00 CT · S406
    Long-term follow-up of Enhertu 3L+ for gastric: DESTINY-Breast-529
    E. Winer, P. Schmid, S. Modi, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  108. Abstract 92192026-09-02 · 21:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-611
    M. Krop, J. Cortes, S. Modi · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  109. Abstract 93592026-09-04 · 16:15 CT · Hall B1
    FLAURA-314: Tagrisso (osimertinib) maintenance in NSCLC
    C. Robert, C. Saura, S. Antonia · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  110. Abstract 15412026-09-02 · 18:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-431 study)
    R. Herbst, T. Mok, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  111. Abstract 96332026-09-04 · 19:15 CT · S100A
    CheckMate-409: Opdivo (nivolumab) neoadjuvant in NSCLC
    M. Reck, M. Krop · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  112. Abstract 10962026-09-02 · 16:15 CT · Hall B1
    MONARCH-199: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    P. Schmid, L. Paz-Ares, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  113. Abstract 99832026-09-03 · 19:45 CT · S100A
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-51
    R. Herbst, G. Curigliano, C. Saura, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  114. Abstract 98932026-09-02 · 15:15 CT · E450
    PACIFIC-104: Imfinzi (durvalumab) adjuvant in SCLC
    H. Rugo, L. Paz-Ares, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  115. Abstract 94062026-09-02 · 14:00 CT · E450
    IMpower-409: Tecentriq (atezolizumab) maintenance in NSCLC
    S. Antonia, C. Saura, C. Robert, et al. · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  116. Abstract 90742026-09-04 · 16:30 CT · E450
    PACIFIC-250: Imfinzi (durvalumab) 3L+ in SCLC
    E. Winer, L. Paz-Ares, P. Schmid, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  117. Abstract 90812026-09-04 · 20:00 CT · Hall B1
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-534
    S. Modi, E. Winer · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  118. Abstract 16492026-09-02 · 13:15 CT · S100A
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-616
    S. Antonia, H. Borghaei, M. Reck · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  119. Abstract 49342026-09-02 · 21:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-105 study)
    P. Schmid, N. Rizvi · Royal Marsden Hospital
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  120. Abstract 95562026-09-05 · 18:30 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-840
    N. Rizvi, M. Reck · Stanford Cancer Institute
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  121. Abstract 93262026-09-05 · 16:15 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    S. Tolaney, H. Borghaei, T. Mok, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  122. Abstract 14482026-09-04 · 20:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-818
    S. Antonia, F. Andre, M. Krop · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 47172026-09-04 · 13:45 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-505
    S. Modi, L. Paz-Ares, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  124. Abstract 10142026-09-01 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-655
    E. Winer, L. Paz-Ares, S. Antonia, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  125. Abstract 90162026-09-05 · 13:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-88 study)
    S. Antonia, S. Peters, H. Rugo, et al. · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  126. Abstract 41712026-09-01 · 13:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-473
    P. Schmid, J. Cortes, M. Reck · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  127. Abstract 10592026-09-01 · 19:00 CT · Hall B1
    PALOMA-944: Ibrance (palbociclib) 2L in HR+ breast cancer
    M.C. Garassino, S. Tolaney, S. Antonia, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 98222026-09-02 · 18:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-18
    C. Robert, E. Winer, J. Brahmer, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  129. Abstract 19992026-09-02 · 16:30 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-663
    S. Antonia, C. Saura · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 97752026-09-03 · 20:00 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    C. Saura, F. Andre, M. Reck · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  131. Abstract 95972026-09-01 · 13:30 CT · E450
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    S. Tolaney, M. Reck, A. Spira, et al. · University of Chicago
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  132. Abstract 59172026-09-04 · 14:00 CT · Hall B1
    Long-term follow-up of Lynparza neoadjuvant for prostate: OlympiA-691
    S. Tolaney, C. Robert, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  133. Abstract 12242026-09-01 · 14:00 CT · E450
    MONALEESA-643: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    S. Modi, M. Krop, S. Peters · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 90372026-09-02 · 21:00 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    T. Mok, C. Robert, J. Cortes, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  135. Abstract 58652026-09-02 · 15:00 CT · S100A
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-380
    J. Brahmer, S. Modi, S. Antonia, et al. · University of Chicago
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  136. Abstract 17722026-09-04 · 16:00 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-998
    H. Borghaei, G. Curigliano, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 15572026-09-03 · 13:45 CT · S100A
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-236
    C. Saura, M. Reck, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  138. Abstract 48392026-09-01 · 14:30 CT · S406
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-792
    S. Antonia, F. Andre, M. Krop, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  139. Abstract 54552026-09-04 · 18:15 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in prostate
    H. Borghaei, N. Rizvi, M. Krop, et al. · Karolinska Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  140. Abstract 42202026-09-02 · 16:30 CT · E450
    DESTINY-Breast-50: Enhertu (trastuzumab deruxtecan) 2L in gastric
    S. Tolaney, R. Herbst · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  141. Abstract 91732026-09-05 · 16:15 CT · S100A
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-278
    G. Curigliano, S. Tolaney, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  142. Abstract 16732026-09-02 · 13:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-231 study)
    T. Mok, C. Saura · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  143. Abstract 94612026-09-01 · 18:30 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-367
    C. Robert, P. Schmid, M.C. Garassino · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  144. Abstract 11372026-09-01 · 18:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    T. Mok, S. Antonia, J. Cortes · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  145. Abstract 11992026-09-01 · 21:00 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    E. Winer, R. Herbst · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 93632026-09-02 · 14:30 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    T. Mok, M.C. Garassino, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  147. Abstract 100062026-09-03 · 15:30 CT · S406
    KEYNOTE-808: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    J. Cortes, A. Spira, C. Robert, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  148. Abstract 40662026-09-04 · 20:45 CT · S100A
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-369 study)
    C. Saura, J. Cortes · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  149. Abstract 17192026-09-02 · 21:30 CT · Hall B1
    MONARCH-922: Verzenio (abemaciclib) 2L in HR+ breast cancer
    M. Krop, C. Robert · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  150. Abstract 99312026-09-02 · 20:00 CT · S100A
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-102
    S. Modi, S. Peters · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  151. Abstract 43792026-09-05 · 18:45 CT · S406
    EV-274: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    C. Saura, S. Tolaney · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  152. Abstract 52532026-09-04 · 19:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-502
    J. Brahmer, M. Reck, M.C. Garassino · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  153. Abstract 17532026-09-03 · 16:30 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-302
    C. Robert, S. Peters · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  154. Abstract 15622026-09-04 · 18:45 CT · Arie Crown Theater
    PALOMA-516: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    N. Rizvi, F. Andre, G. Curigliano, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  155. Abstract 103182026-09-03 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-805
    H. Borghaei, R. Herbst, M. Reck, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  156. Abstract 45622026-09-02 · 18:15 CT · S100A
    Quality of life outcomes with Enhertu in patients with gastric
    H. Rugo, M. Reck, S. Peters · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  157. Abstract 92152026-09-03 · 16:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-903 study)
    N. Rizvi, S. Peters, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  158. Abstract 13632026-09-03 · 13:30 CT · Arie Crown Theater
    MONALEESA-566: Kisqali (ribociclib) 2L in HR+ breast cancer
    S. Modi, H. Borghaei · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  159. Abstract 91592026-09-05 · 16:00 CT · S100A
    FLAURA-777: Tagrisso (osimertinib) maintenance in NSCLC
    T. Mok, J. Brahmer, S. Tolaney, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  160. Abstract 95602026-09-05 · 20:30 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-669 study)
    A. Spira, P. Schmid · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  161. Abstract 11122026-09-05 · 19:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-492
    N. Rizvi, L. Paz-Ares, H. Rugo, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  162. Abstract 18202026-09-02 · 16:00 CT · S100A
    DESTINY-Breast-424: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    C. Saura, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  163. Abstract 19702026-09-03 · 21:00 CT · E450
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-705
    S. Antonia, C. Saura, J. Cortes, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  164. Abstract 45272026-09-03 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-338 study)
    E. Winer, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  165. Abstract 17692026-09-02 · 15:15 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-327
    A. Spira, M. Reck · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  166. Abstract 40232026-09-01 · 14:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-828
    S. Tolaney, C. Robert, H. Borghaei · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  167. Abstract 15492026-09-03 · 15:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-798
    L. Paz-Ares, G. Curigliano · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  168. Abstract 48882026-09-04 · 13:00 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-266
    S. Tolaney, H. Borghaei, A. Spira · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  169. Abstract 17062026-09-03 · 20:45 CT · E450
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-908
    S. Modi, J. Cortes, R. Herbst, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  170. Abstract 99072026-09-04 · 15:00 CT · Hall B1
    PACIFIC-486: Imfinzi (durvalumab) adjuvant in SCLC
    S. Tolaney, C. Robert · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  171. Abstract 12532026-09-02 · 16:00 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    P. Schmid, C. Robert, A. Spira · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  172. Abstract 42552026-09-03 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-224
    S. Tolaney, M. Reck, J. Brahmer, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  173. Abstract 19002026-09-04 · 15:15 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-330
    E. Winer, N. Rizvi, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  174. Abstract 59862026-09-05 · 16:45 CT · E450
    OlympiA-769: Lynparza (olaparib) 3L+ in ovarian
    A. Spira, J. Cortes · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  175. Abstract 90522026-09-02 · 13:15 CT · Hall B1
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-490
    G. Curigliano, H. Borghaei, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  176. Abstract 43212026-09-05 · 18:00 CT · S406
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-923 study)
    S. Modi, E. Winer · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  177. Abstract 19332026-09-02 · 15:45 CT · Arie Crown Theater
    PALOMA-379: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    A. Spira, G. Curigliano, S. Tolaney, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  178. Abstract 57032026-09-03 · 21:00 CT · Hall B1
    Long-term follow-up of Lynparza adjuvant for ovarian: OlympiA-653
    M. Reck, L. Paz-Ares, R. Herbst, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  179. Abstract 93672026-09-01 · 18:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-435
    S. Tolaney, J. Cortes, N. Rizvi, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  180. Abstract 60372026-09-04 · 21:30 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-425 study)
    T. Mok, H. Rugo · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  181. Abstract 90292026-09-02 · 13:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-173
    F. Andre, S. Peters, P. Schmid, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  182. Abstract 65882026-09-01 · 14:30 CT · S406
    CheckMate-212: Opdivo (nivolumab) adjuvant in RCC
    E. Winer, G. Curigliano, S. Antonia, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  183. Abstract 99262026-09-04 · 15:15 CT · S100A
    PACIFIC-60: Imfinzi (durvalumab) 3L+ in NSCLC
    M. Reck, C. Robert, C. Saura, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  184. Abstract 59922026-09-04 · 19:30 CT · E450
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-832 study)
    T. Mok, M.C. Garassino, S. Modi · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  185. Abstract 10352026-09-05 · 21:45 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-160
    C. Robert, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  186. Abstract 96022026-09-04 · 14:30 CT · E450
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-908 study)
    J. Cortes, S. Peters, M. Krop, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  187. Abstract 99242026-09-01 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-645
    N. Rizvi, S. Modi, M.C. Garassino, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  188. Abstract 98412026-09-03 · 19:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-319
    G. Curigliano, P. Schmid, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  189. Abstract 47842026-09-01 · 16:00 CT · E450
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-562
    J. Cortes, L. Paz-Ares, S. Peters, et al. · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  190. Abstract 18752026-09-04 · 15:00 CT · S100A
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-349
    M. Reck, G. Curigliano, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  191. Abstract 95732026-09-03 · 14:00 CT · Arie Crown Theater
    FLAURA-652: Tagrisso (osimertinib) 1L in NSCLC
    F. Andre, G. Curigliano, S. Tolaney, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  192. Abstract 61742026-09-03 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-912 study)
    P. Schmid, M.C. Garassino, S. Modi, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  193. Abstract 11352026-09-02 · 14:00 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-82 study)
    N. Rizvi, T. Mok, S. Modi, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  194. Abstract 57422026-09-05 · 19:45 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-160
    F. Andre, E. Winer, A. Spira · Mayo Clinic
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  195. Abstract 93032026-09-05 · 21:45 CT · S100A
    KEYNOTE-987: Keytruda (pembrolizumab) 1L in SCLC
    S. Antonia, S. Tolaney · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  196. Abstract 45492026-09-04 · 13:15 CT · S100A
    EV-566: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    R. Herbst, L. Paz-Ares, S. Peters, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  197. Abstract 57892026-09-04 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 1L for prostate: OlympiA-17
    H. Borghaei, M. Krop, C. Robert · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  198. Abstract 48092026-09-04 · 13:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-3
    C. Saura, J. Cortes, M. Krop, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  199. Abstract 99402026-09-04 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-713
    C. Saura, C. Robert, G. Curigliano, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  200. Abstract 17132026-09-02 · 19:00 CT · Hall B1
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-383
    F. Andre, J. Brahmer, S. Antonia · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.